Satellos Bioscience Inc. Common Stock (MSLE) is a publicly traded the market company. As of May 21, 2026, MSLE trades at $7.35 with a market cap of $148.94M and a P/E ratio of 0.00. MSLE moved +3.43% today. Year to date, MSLE is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $5.50 to $13.39. Analyst consensus is strong buy with an average price target of $22.00. Rallies surfaces MSLE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Satellos Bioscience Schedules 11:30 a.m. ET April 21 Conference Presentation: Satellos Bioscience will present at Bloom Burton & Co. Healthcare Conference on April 21 in Toronto, with CEO Frank Gleeson at 11:30 a.m. ET and CFO Liz Williams in one-on-ones. A webcast and replay via website provide investors access before Phase II SAT-3247 trial data in Duchenne muscular dystrophy.
| Metric | Value |
|---|---|
| Price | $7.35 |
| Market Cap | $148.94M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.39 |
| 52-Week Low | $5.50 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
6 analysts cover MSLE: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $22.00.